QPPV.COM KNOWLEDGE ASSESSMENT

GVP Product- or Population-Specific Considerations III: Pregnancy and Breastfeeding

Test your understanding of the concepts covered by GVP Product- or Population-Specific Considerations III: Pregnancy and Breastfeeding.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is a major inspection concern when an organisation has many pregnancy exposure reports but no controlled outcome follow-up process?

The organisation is collecting too much information The organisation cannot convert exposure observations into the outcome information needed for safety characterisation The organisation has automatically established that the product is unsafe The organisation is prohibited from using pregnancy reports in signal management

Question 2 of 10 A medicine is detected in breast milk, but no reaction is observed in the infant. What is the most appropriate conclusion?

The finding proves there was no clinically relevant infant exposure The finding proves the medicine is safe for all breastfed infants The result should be interpreted in light of infant dose, pharmacology, age, maturity and clinical follow-up The medicine must be contraindicated during breastfeeding

Question 3 of 10 What is the most appropriate approach to exposure before conception?

Use the date of conception as an absolute boundary for all products Assume pre-conception exposure is irrelevant once treatment stops Define the relevant window using the medicine's persistence and biological effects Treat every pre-conception exposure as equivalent to exposure throughout pregnancy

Question 4 of 10 Which statement best distinguishes prospective from retrospective pregnancy information?

Prospective information is always valid and retrospective information is always invalid Retrospective information is always more reliable because the outcome is known Their evidential contribution depends on design and data quality; retrospective information may be more vulnerable to recall and selective reporting The distinction matters only for regulatory reporting deadlines

Question 5 of 10 Why does pharmacovigilance in pregnancy require a broader assessment than routine evaluation in the general adult population?

Because pregnancy automatically makes every medicine an adverse event Because exposure may affect the woman as well as an embryo, fetus, neonate or child, while untreated maternal disease may also create risks Because spontaneous reports cannot be used for pregnant women Because only fetal outcomes are relevant during pregnancy

Question 6 of 10 A woman with serious disease is considering stopping an effective medicine after discovering she is pregnant. What should a balanced pharmacovigilance communication include?

An instruction to stop treatment immediately in all cases Only the potential fetal risk, because maternal disease is outside pharmacovigilance Known or suspected medicine risks, uncertainty, treatment benefits and the potential consequences of untreated disease A statement that pregnancy exposure is harmless unless an anomaly is reported

Question 7 of 10 Which statement best describes the exposure model during breastfeeding?

The infant is exposed through breast milk, so maternal dose is irrelevant Detection of medicine in milk is equivalent to direct therapeutic dosing of the infant Clinical relevance depends on milk transfer, timing, infant intake, bioavailability and the infant's ability to handle the medicine Only maternal adverse reactions need to be assessed

Question 8 of 10 Which communication approach best supports decision-making when quantitative risk estimates are available but baseline risk is low?

Present only the relative increase because it is more persuasive Present absolute risk where reliable, explain the uncertainty and avoid implying unsupported precision Present only a verbal statement that risk is negligible Avoid all numerical information because patients cannot interpret it

Question 9 of 10 Why are crude counts of congenital anomalies among exposed pregnancies insufficient to establish an increased risk?

Counts are meaningful only when the medicine is administered intravenously A denominator and relevant population context are needed to interpret frequency and comparability Congenital anomalies cannot be reported individually All congenital anomalies have identical background frequencies

Question 10 of 10 What is the primary purpose of proportionate follow-up of a pregnancy report?

To obtain every conceivable personal detail regardless of relevance To clarify exposure, timing, outcomes and clinically important alternative explanations To guarantee that every report has a favourable outcome To replace the need for population-level studies

GVP Product- or Population-Specific Considerations III: Pregnancy and Breastfeeding

Cookie Settings